EGI
ACRS icon

EAM Global Investors’s Aclaris Therapeutics ACRS Stock Holding History

EAM Global Investors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-121,563
Closed -$3.06M – 143
2021
Q1 		$3.06M Buy
+121,563
New +$2.38M 0.85% 28

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

EAM Global Investors's ACRS Position: Q2 2021 in Review

EAM Global Investors sold out of Aclaris Therapeutics (ACRS) in Q2 2021, closing a stake of 121,563 shares — an estimated $3.06M sold.

EAM Global Investors first reported a position in ACRS in Q1 2021 and held it in 1 quarter. The position peaked at $3.06M in Q1 2021. 128 funds tracked by Wall St. Rank hold ACRS as of Q2 2021.

  • EAM Global Investors reported no remaining Aclaris Therapeutics position as of Q2 2021 after selling out during the quarter.
  • EAM Global Investors sold 121,563 Aclaris Therapeutics shares in Q2 2021, an estimated $3.06M.
  • EAM Global Investors first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 1 quarter.
  • EAM Global Investors's Aclaris Therapeutics position peaked at $3.06M in Q1 2021.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2021.

Based on EAM Global Investors's 13F filing for Q2 2021, filed 13 Aug 2021.